Gelonghui, January 26 | Nanhua Biotech (000504.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 19 million yuan to 28 million yuan, down 49.67 percent- 120.56% from the same period last year; net profit loss after deducting non-recurring profit and loss was 33.5 million yuan — 42.5 million yuan, down 45.33% -84.38% from the same period last year; basic earnings loss per share was 0.058 yuan/share — 0.085 yuan/share.

Reasons for changes in performance: 1. During the reporting period, the company's cell testing and storage business fell short of expectations, and revenue declined year-on-year due to the termination of the company's heating business operations; 2. During the reporting period, various assets were prepared for impairment as of December 31, 2023 in accordance with relevant regulations such as corporate accounting standards and company accounting policies; 3. During the reporting period, the company increased investment in channel construction, product upgrades and R&D expenses to expand revenue sources and enhance business competitiveness.